

Claim Listing

1-22. (Canceled).

23. (Currently Amended) An adjuvant composition consisting essentially of: ~~(A) an ionic polysaccharide; and (B) an immunostimulating complex that comprises (i) a saponin and (ii) cholesterol, wherein the mass ratio of the ionic polysaccharide to the immunostimulating complex is in the range of 50 to 300~~ of an ionic polysaccharide component and a saponin component, wherein the saponin component is an immunostimulatory complex.

24. (Currently Amended) The adjuvant composition of claim 23, wherein ~~the~~ an ionic polysaccharide is an ionic dextran.

25. (Currently Amended) The adjuvant composition of claim 24, wherein ~~the~~ an ionic dextran is DEAE-dextran or QAE-dextran.

26. (Previously Presented) The adjuvant composition of claim 23, wherein the immunostimulating complex is a protein-free immunostimulating complex.

27. (Currently Amended) The adjuvant composition of claim 23, wherein the immunostimulating complex ~~further~~ comprises cholesterol, a phospholipid, phosphatidyl choline, and wherein the saponin is Quil A.

28. (Previously Presented) The adjuvant composition of claim 23, wherein the mass ratio of ionic polysaccharide component to immunostimulating complex component is in the range of about 100 to about 140.

29. (Previously Presented) The adjuvant composition of claim 28, wherein the mass ratio is about 125.

30. (Previously Presented) The adjuvant composition of claim 23, comprising about 10 mg of the ionic polysaccharide and about 80 µg of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.

31. (Previously Presented) The adjuvant composition of claim 23, comprising about 100 mg of the ionic polysaccharide and about 800 µg of the immunostimulating complex, wherein the ionic polysaccharide is DEAE-dextran.

32. (Previously Presented) An immunogenic composition comprising an immunogenic and the adjuvant composition of claim 23.

33. (Previously Presented) The immunogenic composition of claim 32, wherein said immunogen comprises LHRH.

34. (Previously Presented) The immunogenic composition of claim 33, wherein said immunogen comprises an LHRH-diphtheria toxoid conjugate.

35. (Previously Presented) The immunogenic composition of claim 34, comprising from

about 5 to about 500 μg of LHRH-diphtheria toxoid conjugate, from about 5 to about 500 mg of the ionic polysaccharide, and from about 40 to about 4000 μg of the immunostimulating complex.

36. (Previously Presented) A pharmaceutical composition, comprising (i) the immunogenic composition of claim 32, and (ii) one or more pharmaceutically acceptable carriers.

37. (Previously Presented) A method of eliciting an effective immune response in an animal, comprising administering to an animal an effective amount of the immunogenic composition of claim 32.

38. (Previously Presented) The method of claim 37, wherein said composition further comprises one or more pharmaceutically acceptable carriers.

39. (New) The adjuvant composition of Claim 23, wherein the mass ratio of the ionic polysaccharide component to the immunostimulating complex component is in the range of 50 to 300.

40. (New) An adjuvant composition comprising an ionic polysaccharide component and a saponin component, wherein the saponin component is an immunostimulatory complex.

41. (New) The adjuvant composition of claim 40, wherein an ionic dextran is DEAE-dextran or QAE-dextran.

42. (New) The adjuvant composition of claim 40, wherein the immunostimulating complex is a protein-free immunostimulating complex.